PD-L1-targeted CAR-T cell therapy is presumed to kill PD-L1-overexpressing tumor cells and block the PD-1/PD-L1 immune checkpoint, significantly enhancing anti-tumor activity in solid tumors. The gene discussed is CD274; the disease is neoplasm.